CASP2 and neoplasm: In the paper by Ho et al. (2009) that first identified caspase-2 as a tumor suppressor, the authors also noted that caspase-2-deficient MEF proliferated significantly faster than their wild-type counterparts, suggesting a defect in cell cycle control in the absence of caspase-2.